gastroenterology
IBD

Biosimilar switching safe for infliximab in NOR-SWITCH Extension trial

Switching from originator infliximab to a biosimilar, CT-P13 (Inflectra), does not result in any change in efficacy or safety in IBD patients up to 18 months, new results from the NOR-SWITCH extension trial show. Presenting findings from a six-month open label follow up of the 52-week NOR-SWITCH trial,  researchers from Norways told DDW 2018 there ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic